Page 25 - Layout 1
P. 25
MEN’S
HEALTH
In conclusion Alendronate for the treatment of osteoporosis in men.
Over 5 million men have or are at risk for osteoporosis. Though
N Engl J Med. 2000;343(9):604.
less prevalent than in women, morbidity and mortality associated
with osteoporosis is higher in men and they are less likely to have Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski
been evaluated or receive treatment for this condition. So it is im- E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD,
portant that physicians especially those involved in care of the eld- Bolognese MA, McClung MR, Bone HG, LjunggrenÖ, Abraham-
erly and men’s health issues adequately screen and treat these sen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer
individuals. A, Hall JW, Boonen
References A randomized, placebo–controlled study of the effects of deno-
Finkelstein JS. Epidemiology and etiology of osteoporosis in sumab for the treatment of men with low bone mineral density.
men. : UpToDate, Post TW (Ed), UpToDate, Waltham, MA. J Clin Endocrinol Metab. 2012;97(9):3161.
Finkelstein JS. Treatment of osteoporosis in men. : UpToDate,
Post TW (Ed), UpToDate, Waltham, MA. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Re-
ginster JY, Hodsman AB, Eriksen EF, Ish–Shalom S, Genant HK,
Finkelstein JS. Clinical manifestations, diagnosis, and evaluation Wang O, Mitlak BH
of osteoporosis in men. : UpToDate, Post TW (Ed), UpToDate,
Waltham, MA. (Accessed November 6, 2015) Effect of parathyroid hormone (1–34) on fractures and bone
Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab mineral density in postmenopausal women with osteoporosis.
Clin North Am 2007; 36:399.
N Engl J Med. 2001;344(19):1434.
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J,
Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lom-
bardi A
visit us at www.bcms.org 25
